Stockscreener 앱 받기
103.09
1.12%
1.14
시간 외 거래:
103.00
-0.09
-0.09%
전일 마감가:
$101.95
열려 있는:
$103.56
하루 거래량:
7.79M
Relative Volume:
0.72
시가총액:
$178.39B
수익:
$46.59B
순이익/손실:
$5.41B
주가수익비율:
33.32
EPS:
3.0938
순현금흐름:
$7.38B
1주 성능:
-4.84%
1개월 성능:
-7.33%
6개월 성능:
-4.57%
1년 성능:
-22.91%
1일 변동 폭
$102.57
$104.44
1주일 범위
$101.49
$108.39
52주 변동 폭
$81.97
$137.49
애보트 래버러토리스 Stock (ABT) Company Profile
명칭
Abbott Laboratories
전화
(224) 667-6100
주소
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Compare ABT vs MDT, SYK, BSX, EW
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
103.09 | 176.41B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
93.80 | 116.35B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
281.87 | 105.70B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
45.05 | 62.29B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
85.52 | 48.63B | 6.30B | 1.07B | 1.09B | 1.8406 |
애보트 래버러토리스 Stock (ABT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-22 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2025-10-10 | 개시 | The Benchmark Company | Buy |
| 2025-07-18 | 업그레이드 | Jefferies | Hold → Buy |
| 2025-06-16 | 개시 | Leerink Partners | Market Perform |
| 2024-10-08 | 개시 | Oppenheimer | Outperform |
| 2024-09-19 | 개시 | Piper Sandler | Overweight |
| 2024-07-30 | 다운그레이드 | Edward Jones | Buy → Hold |
| 2024-05-30 | 개시 | Goldman | Buy |
| 2023-07-21 | 업그레이드 | Wolfe Research | Underperform → Peer Perform |
| 2023-05-30 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2023-04-20 | 재확인 | Barclays | Overweight |
| 2023-04-20 | 재확인 | Bernstein | Outperform |
| 2023-04-20 | 재확인 | JP Morgan | Overweight |
| 2023-04-20 | 재확인 | Raymond James | Outperform |
| 2023-04-20 | 재확인 | UBS | Buy |
| 2023-04-20 | 재확인 | Wolfe Research | Underperform |
| 2023-03-29 | 개시 | UBS | Buy |
| 2022-10-26 | 개시 | Mizuho | Neutral |
| 2022-10-18 | 개시 | Barclays | Overweight |
| 2022-10-12 | 개시 | Jefferies | Hold |
| 2022-07-06 | 개시 | Wolfe Research | Underperform |
| 2022-03-02 | 재개 | BofA Securities | Buy |
| 2022-01-27 | 재확인 | Credit Suisse | Outperform |
| 2022-01-27 | 재확인 | Morgan Stanley | Overweight |
| 2022-01-27 | 재확인 | Raymond James | Outperform |
| 2022-01-27 | 재확인 | UBS | Buy |
| 2021-12-10 | 개시 | RBC Capital Mkts | Outperform |
| 2021-10-27 | 업그레이드 | Atlantic Equities | Neutral → Overweight |
| 2021-10-14 | 개시 | Redburn | Neutral |
| 2021-05-25 | 개시 | Barclays | Overweight |
| 2021-04-15 | 개시 | Atlantic Equities | Neutral |
| 2021-01-28 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2020-09-11 | 개시 | Wolfe Research | Outperform |
| 2020-06-01 | 다운그레이드 | Goldman | Neutral → Sell |
| 2020-03-05 | 개시 | Citigroup | Buy |
| 2020-02-13 | 개시 | Goldman | Neutral |
| 2020-02-06 | 재개 | BTIG Research | Neutral |
| 2020-01-02 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2019-06-13 | 재확인 | BofA/Merrill | Buy |
| 2019-02-07 | 재확인 | BofA/Merrill | Buy |
| 2019-01-02 | 다운그레이드 | Citigroup | Neutral → Sell |
| 2018-11-30 | 업그레이드 | Goldman | Neutral → Buy |
| 2018-10-16 | 개시 | Barclays | Overweight |
| 2018-06-27 | 개시 | Bernstein | Outperform |
| 2018-01-30 | 재확인 | Citigroup | Neutral |
| 2018-01-25 | 재확인 | Stifel | Buy |
| 2018-01-25 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2018-01-03 | 개시 | Evercore ISI | Outperform |
| 2018-01-02 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2018-01-02 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2017-10-19 | 재확인 | RBC Capital Mkts | Outperform |
| 2017-10-19 | 재확인 | Stifel | Buy |
모두보기
애보트 래버러토리스 주식(ABT)의 최신 뉴스
Two Medical Device Dividend Giants, One Better Buy: Medtronic vs. Abbott - AOL.com
Abbott Laboratories Stock (ABT) Opinions on Analyst Buy Rating Reiteration - Quiver Quantitative
Is Abbott Laboratories (ABT) Reasonably Priced After Its FDA Win? - simplywall.st
Abbott Laboratories stock underperforms Friday when compared to competitors - MarketWatch
Abbott Laboratories stock gains as Citi lifts price target and guidance stays firm - ad-hoc-news.de
Abbott Cancer Diagnostics Targets Prospective Studies for MCED Test a Year After Launch - GenomeWeb
Investors Heavily Search Abbott Laboratories (ABT): Here is What You Need to Know - Yahoo Finance
The Zacks Analyst Blog Highlights Goldman Sachs, RTX, Abbott, NLI and Precipio - Yahoo Finance
Abbott Laboratories Share Price Today (ABT) | Live Chart, News & Stock Market - TechGraph
Abbott Laboratories stock heads into the open after a 0.4% dip - ad-hoc-news.de
Abbott Laboratories stock underperforms Thursday when compared to competitors - MarketWatch
Top Research Reports for Goldman Sachs, RTX & Abbott - finance.yahoo.com
Abbott Spinal Cord Stimulator Explant Surgery Required After Device Failure: Lawsuit - AboutLawsuits.com
Abbott Laboratories stock falls after FDA approval - ad-hoc-news.de
Abbott Laboratories stock before the bell falls 2.6 percent - ad-hoc-news.de
Abbott Laboratories (ABT) Secured FDA Approval, Is It Still 11% Below Fair Value? - simplywall.st
Abbott Wins FDA Clearance for Dual-Energy AFib Catheter - finance.biggo.com
Abbott partners with Sengkang General Hospital to advance early detection of muscle loss in Singapore - BioSpectrum Asia
Abbott Is Selling Sterility as a Feature. In Liquid Formula It Is Already the Rule. - marlerblog.com
Abbott Receives FDA Nod for TactiFlex Duo: Stock to Gain? - Yahoo Finance
Abbott garners FDA nod for its TactiFlex catheter to treat AFib - Fierce Biotech
Abbott’s dual ablation catheter lands FDA approval - Yahoo Finance
Wells Fargo Maintains Abbott Laboratories(ABT.US) With Buy Rating, Maintains Target Price $112 - Moomoo
Abbott Laboratories stock gains after FDA approval and strong guidance - ad-hoc-news.de
Abbott Laboratories stock heads into the open after a modest loss - ad-hoc-news.de
Here's Why Abbott (ABT) Fell More Than Broader Market - finance.yahoo.com
Abbott Laboratories stock underperforms Tuesday when compared to competitors - MarketWatch
1 No-Brainer ETF I'm Loading Up on in 2026 and Beyond - The Motley Fool
FDA approves new Abbott catheter capable of PFA and radiofrequency ablation - Cardiovascular Business
Abbott wins FDA approval for dual-energy ablation catheter - MedTech Dive
Abbott receives FDA approval for AFib ablation catheter - grafa.com
Abbott Laboratories (ABT) Won FDA Approval For Its TactiFlex Duo Catheter - simplywall.st
Abbott scores another win at UPC with SiBio preliminary injunction - IAM Patent
Abbott receives FDA approval for dual-energy heart ablation catheter By Investing.com - Investing.com Canada
Abbott wins FDA nod for cardiac ablation catheter (ABT:NYSE) - Seeking Alpha
The FDA Clears an Abbott Product - marketscreener.com
10.5 million people in the U.S. live with hearts that beat too fast, too slow or irregularly. Abbott gets FDA approval. - Stock Titan
Abbott Laboratories stock holds firm after July earnings - AD HOC NEWS
Abbott Laboratories (NYSE:ABT): Can Heart Research Lift Its Next Move? - Kalkine Media
Abbott Blocks Rival's Glucose Monitor Sales In Europe - Law360
Abbott Laboratories stock holds valuation premium amid steady earnings - ad-hoc-news.de
Abbott Laboratories (ABT) Stock Analysis: Analyst Consensus Reveals a 10.96% Upside Potential - DirectorsTalk Interviews
Abbott Stock And Other Defensive Dividend Picks For Uncertain Markets - simplywall.st
Abbott Laboratories stock holds near $108 after strong Q2 - AD HOC NEWS
Abbott Laboratories Profile: Recipients - opensecrets.org
Abbott Laboratories (ABT) Q2 2026 Earnings Call Transcript - Fortune
How New Diabetes, Cardiac, Nutrition and Cancer Tools At Abbott Laboratories (ABT) Have Changed Its Investment Story - simplywall.st
Abbott CFO Philip P. Boudreau Retains 70,784 Shares After Forfeiting 388 Shares at $110.36 Each - Kalkine Media
Ferguson Wellman Capital Management Inc. Sells 136,385 Shares of Abbott Laboratories $ABT - InsuranceNewsNet
Renal Denervation Market Size, Share & Trends Analysis - GlobeNewswire Inc.
US companies face rise in cyber attacks - Reuters
애보트 래버러토리스 (ABT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.12%
자본화:
|
볼륨(24시간):